Trials / Completed
CompletedNCT02569242
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 419 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | |
| DRUG | Docetaxel/Paclitaxel |
Timeline
- Start date
- 2015-12-14
- Primary completion
- 2020-10-23
- Completion
- 2020-10-23
- First posted
- 2015-10-06
- Last updated
- 2022-07-06
- Results posted
- 2022-01-14
Locations
89 sites across 8 countries: United States, Denmark, Germany, Italy, Japan, South Korea, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02569242. Inclusion in this directory is not an endorsement.